During the past decade, Schwerpunktpraxis für Entwicklung und Lernen conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Schwerpunktpraxis für Entwicklung und Lernen" are "ADHD" (1 trials), "Attention Deficit Hyperactivity Disorder (ADHD)" (1 trials) and "Attention-Deficit/Hyperactivity Disorder" (1 trials). Many other conditions were trialed in "Schwerpunktpraxis für Entwicklung und Lernen" in a lesser frequency.

Most popular intervention types in "Schwerpunktpraxis für Entwicklung und Lernen" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Atomoxetine Hydrochloride" (1 trials), "Lisdexamfetamine Dimesylate" (1 trials), "Lisdexamfetamine dimesylate" (1 trials), "Lisdexamfetamine dimesylate (LDX)" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Schwerpunktpraxis für Entwicklung und Lernen" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Schwerpunktpraxis für Entwicklung und Lernen". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Schwerpunktpraxis für Entwicklung und Lernen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Schwerpunktpraxis für Entwicklung und Lernen, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".